Corient Private Wealth LP Takes Position in Bicara Therapeutics Inc. $BCAX

Corient Private Wealth LP bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 2nd quarter, Holdings Channel.com reports. The firm bought 36,683 shares of the company’s stock, valued at approximately $1,089,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in Bicara Therapeutics by 87.5% in the fourth quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock valued at $126,000 after acquiring an additional 3,500 shares in the last quarter.

Bicara Therapeutics Trading Down 0.7%

Shares of NASDAQ:BCAX opened at $23.17 on Friday. The firm has a market cap of $1.53 billion, a PE ratio of -7.47 and a beta of -0.82. The company has a fifty day simple moving average of $26.48 and a 200 day simple moving average of $22.68. Bicara Therapeutics Inc. has a 12-month low of $10.30 and a 12-month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting analysts’ consensus estimates of ($0.82). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BCAX shares. Wells Fargo & Company boosted their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. BTIG Research raised their price target on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Finally, The Goldman Sachs Group upped their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.64.

Insider Activity

In other news, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $279,800.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at $10,133,012.96. This trade represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 108,000 shares of company stock worth $3,079,236. 13.80% of the stock is currently owned by corporate insiders.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.